NanoViricides, Inc.

Equities

NNVC

US6300873022

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2.18 ^USD	+3.07%		-3.54%	+113.73%

May. 14	NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	CI
May. 08	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	CI

NanoViricides Appoints Meeta Vyas as an Interim CFO

May 13, 2013 at 03:45 pm EDT

NanoViricides has hired Meeta Vyas as an interim CFO, which the company says will strengthen its executive team as it moves its drug candidates toward clinical trials. Vyas, who is married to president and chairman of NanoViricides Anil R. Diwan. Vyas moved on to become the CEO of the World-Wide Fund for Nature - India (WWF-India) and then VP of the National Audubon Society (USA).

Latest news about NanoViricides, Inc.

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	May. 14	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	May. 08	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	May. 06	CI
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	Apr. 30	CI
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	Feb. 01	CI
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	Jan. 29	CI
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	Nov. 28	CI
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	Nov. 14	CI
North American Morning Briefing : Geopolitical -2-	23-10-18	DJ
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-13	CI
North American Morning Briefing : Stock Futures -2-	23-10-11	DJ
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2	23-08-21	CI
Health Care Down on Cyclical Rotation -- Health Care Roundup	23-07-11	DJ
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides	23-07-11	CI
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well	23-07-06	CI
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun	23-06-29	CI
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
NanoViricides Files $150 Million Mixed Shelf	23-05-08	MT
NanoViricides, Inc. Enters into License Agreement with Karveer Meditech Private Limited	23-03-31	CI
EF Hutton Lowers Price Target on NanoViricides to $5.25 From $8.50, Maintains Buy Rating	23-02-28	MT
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-14	CI
North American Morning Briefing : Stock Futures -3-	23-02-10	DJ
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-14	CI

Chart NanoViricides, Inc.

Duration

Period

More charts

Company Profile

NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Sector

Biotechnology & Medical Research

Calendar

2024-11-17 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.18 USD

Average target price

6.5 USD

Spread / Average Target

+198.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NANOVIRICIDES, INC.	+113.73%	25.68M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs